Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02083783 · ClinicalTrials.gov registry record · Phase 3
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 3 study of Attention Deficit Disorder With Hyperactivity, sponsored by Tris Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 108
- Enrollment target
- 5
- Study locations
NCT02083783 is a Phase 3 study of Attention Deficit Disorder With Hyperactivity that has completed, run by Tris Pharma. The registered enrollment target is 108 participants, below the 350-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (69% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02083783, a Phase 3 study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by Tris Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 108 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG TRI102
Study Locations (5)
Texas
- Bayou City Research - Houston
- Westex Clinical Investigation - Lubbock
California
- Newport Beach Clinical Research Associates, Inc. - Newport Beach
Nevada
- Center for Psychiatry and Behavioral Medicine, Inc. - Las Vegas
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02083783
The ClinicalTrials.gov registry entry for NCT02083783 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 350-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (69% lower). The listed sponsor is Tris Pharma, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02083783 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Nevada.
Frequently Asked Questions
What is clinical trial NCT02083783 about?
NCT02083783 is a clinical study titled "TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)". The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
What is the current status of trial NCT02083783?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 108 participants. The study started on 2014-03. Estimated completion is 2014-12.
What conditions does trial NCT02083783 study?
This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT02083783?
The interventions under investigation include: Placebo (OTHER), TRI102 (DRUG).
Who is sponsoring clinical trial NCT02083783?
This trial is sponsored by Tris Pharma, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02083783 being conducted?
This trial has 5 study locations across California, Nevada, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Disorder With Hyperactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
ACTIVE NOT RECRUITING
-
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
COMPLETED · Phase 2
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · NA
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder in Adults
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.